These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8052356)

  • 1. Age and dialysis-related amyloidosis.
    Baldrati L; Docci D; Tomidei G; Capponcini C; Neri L; Feletti C
    Nephron; 1994; 67(1):120. PubMed ID: 8052356
    [No Abstract]   [Full Text] [Related]  

  • 2. Haemodialysis membranes, serum beta 2-microglobulin, and dialysis amyloidosis.
    Hauglustaine D; Waer M; Michielsen P; Goebels J; Vandeputte M
    Lancet; 1986 May; 1(8491):1211-2. PubMed ID: 2871445
    [No Abstract]   [Full Text] [Related]  

  • 3. Dialysis-related amyloidosis: importance of biocompatibility and age.
    Jadoul M
    Nephrol Dial Transplant; 1998; 13 Suppl 7():61-4. PubMed ID: 9870440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible role of dialysis membrane characteristics in amyloid osteoarthropathy.
    Vandenbroucke JM; Jadoul M; Maldague B; Huaux JP; Noël H; van Ypersele de Strihou C
    Lancet; 1986 May; 1(8491):1210-1. PubMed ID: 2871444
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of dialysis membrane on serum beta 2-microglobulin (beta 2M) in chronic haemodialysis patients.
    Farrell J; Bastani B
    Nephrol Dial Transplant; 1997 Apr; 12(4):856. PubMed ID: 9141041
    [No Abstract]   [Full Text] [Related]  

  • 6. Expression of beta2-microglobulin and c-fos mRNA: is there an influence of high- or low-flux dialyzer membranes?
    Haufe CC; Eismann U; Deppisch RM; Stein G
    Kidney Int Suppl; 2001 Feb; 78():S177-81. PubMed ID: 11169006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemofiltration and the middle molecule.
    Henderson LW
    Blood Purif; 1999; 17(4):175-7. PubMed ID: 10494018
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical, morphologic, biochemical, and immunohistochemical aspects of dialysis-associated amyloidosis.
    Hampl H; Lobeck H; Bartel-Schwarze S; Stein H; Eulitz M; Linke RP
    ASAIO Trans; 1987; 33(3):250-9. PubMed ID: 3675951
    [No Abstract]   [Full Text] [Related]  

  • 9. Beta 2-microglobulin associated amyloidosis and therapy with high flux hemodialysis membranes.
    Floege J; Koch KM
    Clin Nephrol; 1994 Jul; 42 Suppl 1():S52-6. PubMed ID: 7923985
    [No Abstract]   [Full Text] [Related]  

  • 10. Nodular amyloidosis.
    Younai F; Sciubba JJ
    J Oral Pathol Med; 1993 May; 22(5):231-4. PubMed ID: 8315603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Amyloidosis of the dialysis patient].
    van Ypersele de Strihou C
    Bull Mem Acad R Med Belg; 1988; 143(10-12):456-65; discussion 465-7. PubMed ID: 3077074
    [No Abstract]   [Full Text] [Related]  

  • 12. Evolution of serum prealbumin following hemodialysis: effect of different dialysis membranes.
    Docci D; Bilancioni R; Pistocchi E; Baldrati L; Capponcini C; Delvecchio C; Feletti C
    Nephron; 1992; 62(2):145-9. PubMed ID: 1436305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly permeable and biocompatible membranes and prevalence of dialysis-associated arthropathy.
    Kessler M; Netter P; Maheut H; Wolf C; Prenat E; Huu TC; Gaucher A
    Lancet; 1991 May; 337(8749):1092-3. PubMed ID: 1673510
    [No Abstract]   [Full Text] [Related]  

  • 14. Ubiquitin in dialysis amyloidosis.
    Okada M; Miyazaki S; Hirasawa Y
    Nephron; 1995; 70(1):125-6. PubMed ID: 7617100
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of complement activation by hemodialysis membranes.
    Cheung AK; Henderson LW
    Am J Nephrol; 1986; 6(2):81-91. PubMed ID: 3518458
    [No Abstract]   [Full Text] [Related]  

  • 16. Biocompatibility criteria in hemodialysis.
    Cordonnier DJ; Forêt M
    Contrib Nephrol; 1989; 71():30-5. PubMed ID: 2680263
    [No Abstract]   [Full Text] [Related]  

  • 17. Dialysis membranes inhibit synthesis and release of beta 2-microglobulin in lymphocyte culture.
    Campistol JM; Molina R; Rodriguez R; Mirapeix E; Muñoz-Gomez J; Revert L
    Nephron; 1991; 59(4):691-2. PubMed ID: 1809274
    [No Abstract]   [Full Text] [Related]  

  • 18. Influence of dialysis membranes on the development of dialysis-related amyloidosis.
    Miura Y; Ishiyama T; Okada M; Nakamaru T; Morita H
    Contrib Nephrol; 1995; 112():129-36. PubMed ID: 7554984
    [No Abstract]   [Full Text] [Related]  

  • 19. Biocompatibility study on cuprophane and polysulphone dialysers.
    Taraba I; Polner K; Makó J
    Nephrol Dial Transplant; 1991; 6 Suppl 3():22-5. PubMed ID: 1775261
    [No Abstract]   [Full Text] [Related]  

  • 20. Focusing on membranes.
    von Sengbusch G; Bowry S; Vienken J
    Artif Organs; 1993 Apr; 17(4):244-53. PubMed ID: 8498904
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.